Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil
| Autor: | Alexandra Brentani, Miriam Hatsue Honda Federico, Gilberto de Castro |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Oncology medicine.medical_specialty Cost effectiveness Cost-Benefit Analysis medicine.medical_treatment Kaplan-Meier Estimate CUSTO ECONÔMICO Risk Assessment Statistics Nonparametric Cohort Studies Cost of Illness Internal medicine Confidence Intervals medicine Humans Neoplasm Invasiveness health care economics and organizations Aged Neoplasm Staging Retrospective Studies Aged 80 and over Cisplatin Chemotherapy Radiotherapy business.industry Medical record Head and neck cancer Chemoradiotherapy Cost-effectiveness analysis Middle Aged Prognosis medicine.disease Survival Analysis Surgery Radiation therapy Models Economic Treatment Outcome Otorhinolaryngology Head and Neck Neoplasms Carcinoma Squamous Cell Female business Brazil medicine.drug |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 1043-3074 |
| DOI: | 10.1002/hed.21601 |
| Popis: | Background. The purpose of this study was to analyze the cost-effectiveness of cisplatin-based chemoradiation compared to radiation therapy (RT) alone to treat patients with advanced head and neck cancer in Brazil. Methods. Data were collected retrospectively from the medical records of 33 patients treated with RT alone (strategy 1) and from 29 patients treated with cisplatin-based chemoradiation (strategy 2). The Brazilian National Health System (Sistema Unico de Saude [SUS]) reimbursement parameters perspective was considered, and the effectiveness was measured in years of disease-free life gained. One-way sensitivity analysis was performed to determine robustness of this study. Results. In strategy 1, there were 31% of the patients who lived without disease progression for more than 13 months after treatment, compared to 58% of patients in strategy 2. According to SUS parameters, the total cost per patient in strategy 1 was $1167.00 U.S. dollars and in strategy 2, it was $2058.00 U.S. dollars. Incremental cost-effectiveness ratio (ICER) was $3303.00 U.S. dollars per life-year gained. Conclusion. Cisplatin-based chemoradiation proved to be more cost-effective than RT alone. © 2010 Wiley Periodicals, Inc. Head Neck, 2011 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text